JP2020536903A - アンドロゲン除去療法と共に酢酸アビラテロン及びプレドニゾンを投与することにより前立腺癌を治療する方法 - Google Patents

アンドロゲン除去療法と共に酢酸アビラテロン及びプレドニゾンを投与することにより前立腺癌を治療する方法 Download PDF

Info

Publication number
JP2020536903A
JP2020536903A JP2020520290A JP2020520290A JP2020536903A JP 2020536903 A JP2020536903 A JP 2020536903A JP 2020520290 A JP2020520290 A JP 2020520290A JP 2020520290 A JP2020520290 A JP 2020520290A JP 2020536903 A JP2020536903 A JP 2020536903A
Authority
JP
Japan
Prior art keywords
formulation
acetate
patients
prostate cancer
prednisone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020520290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536903A5 (https=
Inventor
トラン，ナムポーン
Original Assignee
ヤンセン オンコロジー，インコーポレイテッド
ヤンセン オンコロジー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン オンコロジー，インコーポレイテッド, ヤンセン オンコロジー，インコーポレイテッド filed Critical ヤンセン オンコロジー，インコーポレイテッド
Publication of JP2020536903A publication Critical patent/JP2020536903A/ja
Publication of JP2020536903A5 publication Critical patent/JP2020536903A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020520290A 2017-10-11 2018-02-08 アンドロゲン除去療法と共に酢酸アビラテロン及びプレドニゾンを投与することにより前立腺癌を治療する方法 Pending JP2020536903A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570781P 2017-10-11 2017-10-11
US62/570,781 2017-10-11
PCT/US2018/017438 WO2019074536A1 (en) 2017-10-11 2018-02-08 METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY

Publications (2)

Publication Number Publication Date
JP2020536903A true JP2020536903A (ja) 2020-12-17
JP2020536903A5 JP2020536903A5 (https=) 2021-03-11

Family

ID=61283312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520290A Pending JP2020536903A (ja) 2017-10-11 2018-02-08 アンドロゲン除去療法と共に酢酸アビラテロン及びプレドニゾンを投与することにより前立腺癌を治療する方法

Country Status (16)

Country Link
US (2) US20190105332A1 (https=)
EP (1) EP3694604A1 (https=)
JP (1) JP2020536903A (https=)
KR (1) KR20200068689A (https=)
CN (1) CN111542373A (https=)
AU (1) AU2018347804A1 (https=)
BR (1) BR112020007090A2 (https=)
CA (1) CA3077678A1 (https=)
EA (1) EA202090916A1 (https=)
IL (1) IL273826A (https=)
JO (1) JOP20200072A1 (https=)
MA (1) MA50341A (https=)
MX (1) MX2020003830A (https=)
PH (1) PH12020550151A1 (https=)
UA (1) UA124865C2 (https=)
WO (1) WO2019074536A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024506382A (ja) * 2021-02-15 2024-02-13 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
UY39201A (es) * 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898495B (zh) * 2012-11-12 2014-11-26 浙江神洲药业有限公司 醋酸阿比特龙酯的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF CANCER, vol. 84, JPN6021047425, 2017, pages 88 - 101, ISSN: 0004650690 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 377, no. 4, JPN6021047427, 4 June 2017 (2017-06-04), pages 352 - 360, ISSN: 0004827889 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024506382A (ja) * 2021-02-15 2024-02-13 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ

Also Published As

Publication number Publication date
IL273826A (en) 2020-05-31
AU2018347804A1 (en) 2020-04-16
US20200069704A1 (en) 2020-03-05
MX2020003830A (es) 2020-11-06
EP3694604A1 (en) 2020-08-19
KR20200068689A (ko) 2020-06-15
MA50341A (fr) 2020-08-19
US20190105332A1 (en) 2019-04-11
JOP20200072A1 (ar) 2020-04-29
UA124865C2 (uk) 2021-12-01
PH12020550151A1 (en) 2021-02-08
BR112020007090A2 (pt) 2020-09-24
EA202090916A1 (ru) 2020-12-11
CN111542373A (zh) 2020-08-14
CA3077678A1 (en) 2019-04-18
WO2019074536A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
JP7201694B2 (ja) 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
US20240350477A1 (en) Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
US20200069704A1 (en) Methods Of Treating Prostate Cancer
JP2024510612A (ja) ソトラシブ投与レジメン
US20190262330A1 (en) Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
JP2024161428A (ja) 転移性去勢感受性前立腺癌の治療のための抗アンドロゲン剤
US20210393630A1 (en) Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
EP4284374A1 (en) Methods of administrating elagolix
US20250177414A1 (en) Combination therapies for treatment of breast cancer
WO2025027138A1 (en) Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer
CN117580572A (zh) 用安森司坦和帕博西尼治疗乳腺癌
WO2020144649A1 (en) Pharmaceutical composition comprising enzalutamide dispersed in apple sauce
Agent DF/HCC Protocol#: 17-112 TITLE: A Phase IB/II Study of Alectinib Combined with Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC Coordinating Center: DF/HCC* Principal Investigator (PI): Ibiayi Dagogo-Jack, MD

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220719